Mankind Pharma Limited — Board Meeting, 31-07-2025: Outcome of Board Meeting

Mankind Pharma's Board has announced a board meeting where it approved consolidated Q1 FY26 financial results: Revenue hit ₹3,570.35 Cr, with profit at ₹444.62 Cr and EPS of ₹10.62. The Board declared an interim dividend of ₹1 per share (100% on face value), with August 8 set as the record date.

In a strategic move, the company approved acquiring the Women Health Rx business from its wholly-owned subsidiary, BSV, aiming for synergy. This business recorded ₹103.67 Cr turnover in FY25. They also greenlit raising up to ₹1,000 Cr via short-term unsecured instruments. Lastly, Dr. Sanjay Koul's resignation as Chief Marketing Officer was noted. #MankindPharma #Q1FY26 #Dividend #PharmaNews